Shares of Sanofi (NYSE:SNY) were down 2.5% during mid-day trading on Wednesday . The stock traded as low as $37.93 and last traded at $37.99, with a volume of 1,994,097 shares trading hands. The stock had previously closed at $38.97.

Several analysts have issued reports on SNY shares. Zacks Investment Research lowered Sanofi from a “buy” rating to a “hold” rating in a research note on Monday, June 6th. Citigroup Inc. restated a “neutral” rating on shares of Sanofi in a research note on Tuesday, June 28th. TheStreet upgraded Sanofi from a “hold” rating to a “buy” rating in a research note on Wednesday, July 27th. Berenberg Bank reiterated a “hold” rating and set a $93.00 target price on shares of Sanofi in a research note on Monday, August 15th. Finally, BNP Paribas upgraded Sanofi from an “underperform” rating to a “neutral” rating in a research note on Tuesday, September 13th. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and four have issued a buy rating to the company’s stock. Sanofi currently has a consensus rating of “Hold” and a consensus target price of $60.50.

The stock has a 50 day moving average price of $39.51 and a 200 day moving average price of $40.65. The company has a market cap of $98.79 billion, a price-to-earnings ratio of 21.28 and a beta of 1.01.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/sanofi-sny-trading-down-2-5.html

A number of hedge funds have recently bought and sold shares of the stock. Dodge & Cox raised its stake in Sanofi by 3.0% in the second quarter. Dodge & Cox now owns 55,155,913 shares of the company’s stock valued at $2,308,275,000 after buying an additional 1,625,784 shares during the last quarter. Franklin Resources Inc. increased its position in shares of Sanofi by 13.3% in the first quarter. Franklin Resources Inc. now owns 21,232,196 shares of the company’s stock valued at $852,684,000 after buying an additional 2,500,421 shares during the period. Fisher Asset Management LLC increased its position in shares of Sanofi by 0.7% in the second quarter. Fisher Asset Management LLC now owns 13,638,183 shares of the company’s stock valued at $564,894,000 after buying an additional 91,233 shares during the period. Hotchkis & Wiley Capital Management LLC increased its position in shares of Sanofi by 12.5% in the second quarter. Hotchkis & Wiley Capital Management LLC now owns 11,432,112 shares of the company’s stock valued at $478,434,000 after buying an additional 1,267,118 shares during the period. Finally, Boston Partners increased its position in shares of Sanofi by 10,203.3% in the second quarter. Boston Partners now owns 7,402,009 shares of the company’s stock valued at $309,774,000 after buying an additional 7,330,168 shares during the period. Institutional investors and hedge funds own 9.42% of the company’s stock.

Sanofi Company Profile

Sanofi SA is a healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. The Company is organized around three principal activities: Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial. The Company invests in emerging markets, diabetes solutions, vaccines, consumer health care, animal health, genzyme and other products.

5 Day Chart for NYSE:SNY

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.